{"id":240585,"date":"2021-06-20T11:49:13","date_gmt":"2021-06-20T15:49:13","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=240585"},"modified":"2022-09-26T13:41:33","modified_gmt":"2022-09-26T17:41:33","slug":"cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/","title":{"rendered":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The Soberana 02 <\/span><a href=\"https:\/\/oncubanews.com\/en\/tag\/cuban-vaccine-against-covid-19\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">vaccine candidate<\/span><\/a><span style=\"font-weight: 400;\"> against the <\/span><a href=\"https:\/\/oncubanews.com\/en\/coronavirus\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">coronavirus<\/span><\/a><span style=\"font-weight: 400;\">, developed by Cuba\u2019s Finlay Vaccine Institute (IFV), showed a 62% efficacy in the preliminary studies of the third phase of clinical trials, the scientists responsible for the research reported this Saturday.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The director of the IFV, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.<\/span><\/p>\n<blockquote class=\"twitter-tweet\" data-width=\"500\" data-dnt=\"true\">\n<p lang=\"es\" dir=\"ltr\">Con solo 2 dosis,  <a href=\"https:\/\/twitter.com\/hashtag\/Soberana02?src=hash&amp;ref_src=twsrc%5Etfw\">#Soberana02<\/a> alcanz\u00f3 un 62% de eficacia. <a href=\"https:\/\/twitter.com\/hashtag\/CubaEsCiencia?src=hash&amp;ref_src=twsrc%5Etfw\">#CubaEsCiencia<\/a> <a href=\"https:\/\/t.co\/wKGecjx6Wp\">pic.twitter.com\/wKGecjx6Wp<\/a><\/p>\n<p>&mdash; BioCubaFarma (@BioCubaFarma) <a href=\"https:\/\/twitter.com\/BioCubaFarma\/status\/1406403065377329158?ref_src=twsrc%5Etfw\">June 20, 2021<\/a><\/p><\/blockquote>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n<p><span style=\"font-weight: 400;\">This formula, one of the five being studied in Cuba, is a subunit conjugate vaccine \u2014 traditionally very safe \u2014 that combines the virus antigen and tetanus toxoid to stimulate the response of the immune system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">V\u00e9rez described the result as \u201cvery comforting,\u201d because it has been obtained in a scenario of circulation \u201cof the most worrying variants due to their transmissibility.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">He also stressed that these results meet the requirements of the World Health Organization (WHO) to consider a candidate under study as an \u201ceffective vaccine,\u201d since that body establishes a minimum efficacy of 50%.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The IFV scientists advanced that in the coming days the authorization of emergency use of Soberana 02 will be requested from the Center for State Control of Medicines, Equipment and Medical Devices (CECMED), the regulatory body in Cuba.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Once approved for emergency use, Soberana 02 would officially acquire the category of vaccine and would become the first COVID-19 vaccine developed in Latin America.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The result announced today was obtained by an interdisciplinary, independent scientific committee, with professionals from the Pedro Kour\u00ed Institute of Tropical Medicine, the Center for Molecular Immunology and the Ministry of Public Health.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Once the preliminary efficacy result of the two-dose administration scheme is known, the second scheme used in clinical trials, consisting of two doses of Soberana 02 and one dose of Soberana Plus, remains to be seen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to V\u00e9rez, they hope to have this data in about two weeks, and that the efficacy achieved by this three-dose scheme is higher than the <\/span><span style=\"font-weight: 400;\">62%<\/span><span style=\"font-weight: 400;\"> obtained by the two-dose one.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The third phase of clinical trials of Soberana 02, carried out entirely in Havana with a double-blind protocol and placebo group, included 44,010 volunteers aged between 19 and 80 years<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The third phase of studies was also carried out in parallel in Iran, by virtue of an agreement with the Pasteur Institute of that country, which has just announced that at the beginning of next week it could authorize its emergency use \u2014 in that country the Cuban formula has been named Pasteur.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This clinical trial of Soberana 02 in pediatric ages also began this week, initially with a group of children between 12 and 18 years old.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cCongratulations Cuba. On the eve of Father\u2019s Day and 13 months into the search for a Cuban vaccine, it is confirmed that with 2 doses, Soberana 02 reached a good percentage of efficacy. Soon we will know the data with the third dose of Soberana Plus, which must be higher,\u201d Cuban President Miguel D\u00edaz-Canel wrote on Twitter.<\/span><\/p>\n<blockquote class=\"twitter-tweet\" data-width=\"500\" data-dnt=\"true\">\n<p lang=\"es\" dir=\"ltr\">Felicidades <a href=\"https:\/\/twitter.com\/hashtag\/Cuba?src=hash&amp;ref_src=twsrc%5Etfw\">#Cuba<\/a>.En v\u00edsperas del\u00a0<a href=\"https:\/\/twitter.com\/hashtag\/D%C3%ADaDeLosPadres?src=hash&amp;ref_src=twsrc%5Etfw\">#D\u00edaDeLosPadres<\/a>\u00a0y a 13 meses de b\u00fasqueda de una vacuna cubana, se confirma que con 2 dosis,\u00a0<a href=\"https:\/\/twitter.com\/hashtag\/Soberana02?src=hash&amp;ref_src=twsrc%5Etfw\">#Soberana02<\/a>\u00a0alcanz\u00f3 un buen % de eficacia. Pronto sabremos el dato con la tercera dosis, <a href=\"https:\/\/twitter.com\/hashtag\/SoberanaPlus?src=hash&amp;ref_src=twsrc%5Etfw\">#SoberanaPlus<\/a>, que debe ser superior.<a href=\"https:\/\/twitter.com\/hashtag\/CubaViva?src=hash&amp;ref_src=twsrc%5Etfw\">#CubaViva<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/CubaPorLaVida?src=hash&amp;ref_src=twsrc%5Etfw\">#CubaPorLaVida<\/a> <a href=\"https:\/\/t.co\/PqPyCfLuA5\">pic.twitter.com\/PqPyCfLuA5<\/a><\/p>\n<p>&mdash; Miguel D\u00edaz-Canel Berm\u00fadez (@DiazCanelB) <a href=\"https:\/\/twitter.com\/DiazCanelB\/status\/1406397592318230531?ref_src=twsrc%5Etfw\">June 19, 2021<\/a><\/p><\/blockquote>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n<p><span style=\"font-weight: 400;\">Cuba has a second vaccine candidate in the last phase of clinical trials, Abdala, developed by the Center for Genetic Engineering and Biotechnology, and whose efficacy is also expected to be known shortly.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Both Soberana 02 and Abdala have already been administered to tens of thousands of Cubans as health intervention studies and parallel to clinical trials.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to official figures, a bit over two million Cubans, out of a population of 11 million, have received at least one dose of these formulas.<\/span><\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"rrnj2N36WA\"><p><a href=\"https:\/\/oncubanews.com\/en\/coronavirus\/more-than-a-million-persons-inoculated-in-cuba-with-covid-19-vaccine-candidates\/\">More than a million persons inoculated in Cuba with COVID-19 vaccine candidates<\/a><\/p><\/blockquote>\n<p><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;More than a million persons inoculated in Cuba with COVID-19 vaccine candidates&#8221; &#8212; OnCubaNews English\" src=\"https:\/\/oncubanews.com\/en\/coronavirus\/more-than-a-million-persons-inoculated-in-cuba-with-covid-19-vaccine-candidates\/embed\/#?secret=moMUYCp15J#?secret=rrnj2N36WA\" data-secret=\"rrnj2N36WA\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n<p><span style=\"font-weight: 400;\">Cuba is not a member of the COVAX Mechanism of the World Health Organization created for low- and middle-income countries to access vaccines, nor has it purchased them on the international market.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The country, which has been going through the third and worst wave of infections since January, accumulates 166,368 infections and 1,148 deaths from COVID-19 to date.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.<\/p>\n","protected":false},"author":3606,"featured_media":240587,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13915],"tags":[33386],"ppma_author":[33548],"class_list":["post-240585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science-cuba","tag-cuban-vaccine-against-covid-19"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English<\/title>\n<meta name=\"description\" content=\"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English\" \/>\n<meta property=\"og:description\" content=\"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"OnCubaNews English\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-20T15:49:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-26T17:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"668\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"EFE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"EFE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/\"},\"author\":{\"name\":\"EFE\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/4a4376ef86616685852e6d895d4d0eea\"},\"headline\":\"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials\",\"datePublished\":\"2021-06-20T15:49:13+00:00\",\"dateModified\":\"2022-09-26T17:41:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/\"},\"wordCount\":700,\"commentCount\":1,\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg\",\"keywords\":[\"Cuban vaccine against COVID-19\"],\"articleSection\":[\"Science\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#respond\"]}],\"copyrightYear\":\"2021\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/\",\"name\":\"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg\",\"datePublished\":\"2021-06-20T15:49:13+00:00\",\"dateModified\":\"2022-09-26T17:41:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/4a4376ef86616685852e6d895d4d0eea\"},\"description\":\"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg\",\"contentUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg\",\"width\":750,\"height\":668,\"caption\":\"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, shows a vial of the Soberana 02 vaccine candidate in Havana. Photo: Ernesto Mastrascusa\\\/EFE\\\/Archive.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/cuba\\\/science-cuba\\\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\",\"name\":\"OnCubaNews English\",\"description\":\"Revista sobre Cuba\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/4a4376ef86616685852e6d895d4d0eea\",\"name\":\"EFE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=gd23dcd71e12bce3843a7572453d0d981\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=g\",\"caption\":\"EFE\"},\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/author\\\/efe\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English","description":"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English","og_description":"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.","og_url":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/","og_site_name":"OnCubaNews English","article_published_time":"2021-06-20T15:49:13+00:00","article_modified_time":"2022-09-26T17:41:33+00:00","og_image":[{"width":750,"height":668,"url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg","type":"image\/jpeg"}],"author":"EFE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"EFE","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/"},"author":{"name":"EFE","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/4a4376ef86616685852e6d895d4d0eea"},"headline":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials","datePublished":"2021-06-20T15:49:13+00:00","dateModified":"2022-09-26T17:41:33+00:00","mainEntityOfPage":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/"},"wordCount":700,"commentCount":1,"image":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg","keywords":["Cuban vaccine against COVID-19"],"articleSection":["Science"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#respond"]}],"copyrightYear":"2021","copyrightHolder":{"@id":"https:\/\/oncubanews.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/","url":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/","name":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials | OnCubaNews English","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg","datePublished":"2021-06-20T15:49:13+00:00","dateModified":"2022-09-26T17:41:33+00:00","author":{"@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/4a4376ef86616685852e6d895d4d0eea"},"description":"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, specified on state television that the percentage has been obtained from the intermediate study of the results in the volunteers to whom two doses of Soberana 02 were applied 28 days apart.","breadcrumb":{"@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#primaryimage","url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg","contentUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/06\/Vicente-Verez-muestra-frasco-con-Soberana-02-750x668-1.jpg","width":750,"height":668,"caption":"The director of the Finlay Vaccine Institute, Vicente V\u00e9rez, shows a vial of the Soberana 02 vaccine candidate in Havana. Photo: Ernesto Mastrascusa\/EFE\/Archive."},{"@type":"BreadcrumbList","@id":"https:\/\/oncubanews.com\/en\/cuba\/science-cuba\/cuban-soberana-02-vaccine-candidate-shows-62-efficacy-in-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oncubanews.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cuban Soberana 02 vaccine candidate shows 62% efficacy in clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/oncubanews.com\/en\/#website","url":"https:\/\/oncubanews.com\/en\/","name":"OnCubaNews English","description":"Revista sobre Cuba","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncubanews.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/4a4376ef86616685852e6d895d4d0eea","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=gd23dcd71e12bce3843a7572453d0d981","url":"https:\/\/secure.gravatar.com\/avatar\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=g","caption":"EFE"},"url":"https:\/\/oncubanews.com\/en\/author\/efe\/"}]}},"authors":[{"term_id":33548,"user_id":3606,"is_guest":0,"slug":"efe","display_name":"EFE","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/2a1de33ef07ae580021e92116e205cdb099068c1ff1fdba600b998c78b6347eb?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/240585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/users\/3606"}],"replies":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/comments?post=240585"}],"version-history":[{"count":1,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/240585\/revisions"}],"predecessor-version":[{"id":258193,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/240585\/revisions\/258193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media\/240587"}],"wp:attachment":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media?parent=240585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/categories?post=240585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/tags?post=240585"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/ppma_author?post=240585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}